AI summary · may contain errors
In previously treated, RAS-mutant metastatic pancreatic adenocarcinoma, daraxonrasib monotherapy resistance in circulating tumor DNA is linked to RAS-pathway reactivation, seen in 59% of 44 patients.
- 2 cited this week
- Open access
